FLT3 and acute myeloid leukemia: Despite the comparable use of induction chemotherapy and complete remission rates between FLT3-ITD and wild-type FLT3 AML patients, the significantly shorter overall survival in the FLT3-ITD group is consistent with the dismal prognosis associated with this mutation reported in previous studies (4, 5).